Form FDA 2914 Form FDA 2914 Report on Research Use of Radioactive Drugs: Membership

DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION

RADIOACTIVE DRUG RESEARCH COMMITTEE (RDRC)

FOR FDA USE ONLY

Form Approved:
OMB No. 0910-0053.
Expiration Date: 09/30/2023

DATE OF SUBMISSION

REPORT ON RESEARCH USE OF RADIOACTIVE DRUGS
MEMBERSHIP SUMMARY
NOTE: 21 CFR 361.1 Requires that an annual report be submitted by each RDRC. Use Form FDA 2914 to report names and
qualifications of RDRC members and consultants. Also use Form FDA 2915 to add special summaries, as required.
Return COMPLETED form to:
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Drug Evaluation IV
5901-B Ammendale Road
Beltsville, MD 20705-1266

Public reporting burden for this collection of information is
estimated to average 1 hour per response, including the time to review
instructions, search existing data sources, gather and maintain the data
needed, and complete and review the collection of information. Send
comments regarding this burden estimate or any other aspect of this
collection of information, including suggestions for reducing this
burden, to the address on the right.

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
[email protected]
Please do NOT send your completed form
to the PRA Staff email address above.

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of
information unless it displays a currently valid OMB control number.

Attention: RDRC

A. GENERAL INFORMATION
1. RDRC COMMITTEE NUMBER

2. NAME OF INSTITUTION

3. RDRC CHAIRPERSON
a. Name

c. E-mail Address

d. Telephone No. (Include Area Code)

b. Address (Include ZIP code)

e. FAX No. (Include Area Code)

B. REQUIRED MEMBERS (Names and Qualifications)
NOTE: Names must be listed. Qualifications previously submitted to FDA may be incorporated by reference to the appropriate
submission. An individual may not be listed in more than one required specialty.
1. PHYSICIAN(S) RECOGNIZED AS SPECIALIST(S) IN NUCLEAR MEDICINE
Name

Are qualifications attached?

a.

Yes

No

b.

Yes

No

c.

Yes

No

If No, enter date of most recently
submitted curriculum vitae

2. PERSON(S) QUALIFIED BY TRAINING AND EXPERIENCE TO FORMULATE RADIOACTIVE DRUGS
Name

Are qualifications attached?

a.

Yes

No

b.

Yes

No

c.

Yes

No

If No, enter date of most recently
submitted curriculum vitae

3. PERSON(S) WITH SPECIAL COMPETENCE IN RADIATION SAFETY AND RADIATION DOSIMETRY
Name

Are qualifications attached?

a.

Yes

No

b.

Yes

No

c.

Yes

No

FORM FDA 2914 (01/21)

PREVIOUS EDITION IS OBSOLETE.

If No, enter date of most recently
submitted curriculum vitae

PAGE 1 OF 4 PAGES
PSC Publishing Services (301) 443-6740

EF

C. OTHER VOTING MEMBERS NOT LISTED IN SECTION B. (Names and Disciplines; Specialties)
Name and Discipline

Are qualifications attached?

a.

Yes

No

b.

Yes

No

c.

Yes

No

d.

Yes

No

e.

Yes

No

f.

Yes

No

g.

Yes

No

h.

Yes

No

i.

Yes

No

j

Yes

No

k.

Yes

No

If No, enter date of most recently
submitted curriculum vitae

D. COMMITTEE CONSULTANTS (i.e., Pediatrician) (Names and Disciplines; Specialties)

E. NON-VOTING MEMBERS, IF ANY (Names and Position Titles)

F. STUDY SUMMARY TOTAL AND CHAIRPERSON SIGNATURE
1. NUMBER OF STUDY SUMMARIES SUBMITTED IN THIS REPORT
2. SIGNATURE OF RDRC CHAIRPERSON

3. DATE

Unlock
FOR FDA USE ONLY

FORM FDA 2914 (01/21)

PREVIOUS EDITION IS OBSOLETE.

PAGE 2 OF 4 PAGES

Instructions for Completing Radioactive Drug Research Committee (RDRC)
Report on Research Use of Radioactive Drugs -- Membership Summary
(Form FDA 2914)
Basic research with radioactive drugs may be conducted without an Investigational New Drug Application
(IND) when the research is conducted under a FDA-approved Radioactive Drug Research Committee (RDRC)
and other conditions, as specified in the RDRC regulations, are met.
RDRC regulations are contained in Title 21, Code of Federal Regulations, Part 361.1 (21 CFR 361.1) and
maybe accessed at the following web address:
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?FR=361.1
Guidance regarding RDRC procedures is available from the FDA Center for Drug Evaluation and Research,
Office of Drug Evaluation IV, 5901-B Ammendale Road, Beltsville, MD 20705-1266. Information about the
FDA RDRC program is available at the RDRC web site at the following web address:
http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Oncology/ucm093322.htm
Access to RDRC reporting Forms (2914 - Membership Summary and 2915 - Study Summary), which can be
filled out and saved on your computer, can be obtained through the RDRC web site or from the following
FDA Forms website:
http://www.fda.gov/opacom/morechoices/fdaforms/default.html
The following instructions address only the administrative aspects of preparing and submitting Form FDA 2914
(Membership Summary) for the following RDRC submissions:
1. Original Application
An application for FDA approval of a RDRC consists of submission of a cover letter summarizing the
content of the submission, a Form FDA 2914 (Membership Summary), a current and dated curriculum vitae
for each proposed committee member, and a statement that the RDRC agrees to comply with the
requirements under 21 CFR 361.1.
2. Annual Report
The annual report, due on or before January 31 of each year, consists of submission of a cover letter
summarizing the content of the submission, a Form FDA 2914 (Membership Summary), and Form FDA
2915 (Study Summary) for each study conducted during the preceding calendar year. A Form FDA 2915
(Study Summary) should be submitted even for studies that did not enroll any subjects in the preceding
calendar year but have been previously approved by the RDRC and are still open and ongoing.
3. Membership Changes
Changes in membership and applications for new members must be submitted as soon as, or before,
vacancies occur on the committee and consists of submission of Form FDA 2914 (Membership Summary)
and a current and dated curriculum vitae for each proposed committee member.

WHERE TO SEND THE SUBMISSION:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Drug Evaluation IV
5901-B Ammendale Road
Beltsville, MD 20705-1266
ATTN: RDRC

Specific instructions for filling out this report are on the next page.

FORM FDA 2914 (01/21)

PREVIOUS EDITION IS OBSOLETE.

PAGE 3 OF 4 PAGES

FILLING OUT FORM FDA 2914
(Titles and numbers, when used, correspond to the item blocks on Form FDA 2914)

Section A. General Information
1. RDRC Committee Number -- Provide the committee number assigned by FDA when the RDRC was
initially approved. Leave blank for original applications.
2. Name of Institution -- Provide the name of the medical institution to which the RDRC is affiliated. For
annual reports and membership changes, if the name of the medical institution is different from that
provided in the previous submission, please attach a cover letter specifying the old and new names.
3. RDRC Chairperson
a. NAME .................. Provide the name of the chairperson of the RDRC.
b. ADDRESS ............. Provide the address to which written correspondence from FDA should be
directed. If this address is a post office box number, a street address must also be
provided.
c. E-MAIL ............... Provide the e-mail address of the RDRC chairperson to which electronic
correspondences from FDA should be directed.
d. TELEPHONE NO .... Provide the telephone number where the RDRC chairperson is usually available
during normal working hours. A telephone number must be provided.
e. FAX NO .............. Provide the FAX number of the RDRC chairperson to which facsimile
correspondences from FDA should be directed.
MEMBERSHIP - For original applications, annual reports and membership changes, fill in sections B. through E.
referenced below.

Section B. Required Members - Provide the names and qualifications of each required member:
1. Physician recognized as a specialist in nuclear medicine
2. Person qualified by training and experience to formulate radioactive drugs
3. Person with special competence in radiation safety and radiation dosimetry
If there are more than three members in a required speciality, attach a separate sheet.
Attach a current and dated curriculum vitae describing relevant degrees, training, and experience for each
required member. If this is an annual report and qualifications have been previously submitted to FDA,
provide the date of the most recent previous submission for each listed member.
Section C. Other Voting Members Not Listed in Section B - Provide the names, disciplines, and specialties
of other committee members.
Attach a current and dated curriculum vitae for each other voting member. If this is an annual report and
qualifications have been previously submitted to FDA, provide the date of the most recent previous
submission for each listed member.
Section D. Committee Consultants - Provide the names, disciplines, and specialties of committee consultants.
Provide a current and dated CV for each consultant used by the committee during the annual report cycle.
Section E. Non-Voting Members, if any - Provide the names and position titles of non-voting committee
members.
Section F. Study Summary Total and Chairperson Signature
1. Number of Study Summaries Submitted in This Report - For annual reports, provide the number of Study
Summaries included in the submission. For original applications and membership changes, leave blank.
2. Signature of the RDRC Chairperson - The RDRC chairperson must sign the form.
3. Date - Indicate the date the form is signed by the RDRC chairperson.
4. If there are no changes to the FDA Form 2914 from the previously electronically signed FDA Form 2914
or the Chairperson wants to use previously electronically signed FDA Form 2914. Do the following.
• Retrieve the previously electronically signed FDA Form 2914.
• Make changes on previously electronically signed FDA Form 2914.
• Click “Unlock” Signature of Chairperson of Radioactive Drug Research Committee to remove
previously electronically signed signature.
• Click “orange” signature to replace with a new electronic signature.
• Change date.
• Save as a new FDA Form 2914.
FORM FDA 2914 (01/21)

PREVIOUS EDITION IS OBSOLETE.

PAGE 4 OF 4 PAGES